Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: JamesK who wrote (604)	10/28/2021 1:28:54 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 684

Nice, thanks for the pointer. Looks like a hot pick for the tax selling list, exactly what I'm usually looking for as November hits. Gene therapy is poison of late, as you know. But I'll listen to a presentation or two... any near term results due?

To: JamesK who wrote (604)	12/6/2021 12:18:26 PM
From: Area51	Read Replies (2) \| Respond to of 684

<<PASG Passage Bio getting down close to cash value.>> Is it there yet? Another one I think is interesting is BCEL, Per Q3 report they have (Current Assets - Total Liabilities)/37 million shares of 3.18 per share. Currently at 3.31 but closed under 3 on Friday. 27 million per quarter of cash burn, Analyst price target of 24 would be a nice return: marketbeat.com Seems like if someone did a screen now for biotechs trading under cash value they might get several (dozens?) hits. Please post if you find anything that looks good. Thanks, A51